To investigate the role of A 2A adenosine receptors in adaptive responses to chronic intermittent dopamine receptor stimulation, we compared the behavioral sensitization elicited by repeated L-DOPA treatment in hemiparkinsonian wild-type (WT) and A 2A adenosine receptor knock-out (A 2A KO) mice. Although the unilateral nigrostriatal lesion produced by intrastriatal injection of 6-hydroxydopamine was indistinguishable between WT and A 2A KO mice, they developed strikingly different patterns of behavioral sensitization after daily treatment with low doses of L-DOPA for 3 weeks. WT mice initially displayed modest contralateral rotational responses and then developed progressively greater responses that reached a maximum within 1 week and persisted for the duration of the treatment. In contrast, any rotational behavioral sensitization in A 2A KO mice was transient and completely reversed within 2 weeks. Similarly, the time to reach the peak rotation was progressively shortened in WT mice but remained unchanged in A 2A KO mice. Furthermore, daily L-DOPA treatment produced gradually sensitized grooming in WT mice but failed to induce any sensitized grooming in A 2A KO mice. Finally, repeated L-DOPA treatment reversed the 6-OHDA-induced reduction of striatal dynorphin mRNA in WT but not A 2A KO mice, raising the possibility that the A 2A receptor may contribute to L-DOPA-induced behavioral sensitization by facilitating adaptations within the dynorphinexpressing striatonigral pathway. Together these results demonstrate that the A 2A receptor plays a critical role in the development and particularly the persistence of behavioral sensitization to repeated L-DOPA treatment. Furthermore, they raise the possibility that the maladaptive dyskinetic responses to chronic L-DOPA treatment in Parkinson's disease may be attenuated by A 2A receptor inactivation.
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For Ͼ30 years the dopamine precursor L-DOPA has been the most effective and commonly prescribed treatment for Parkinson's disease (PD). Despite its considerable symptomatic motor benefit, chronic administration of L-DOPA leads to abnormal motor responses known as dyskinesias, involving involuntary choreic or dystonic movements in Ͼ50% of patients (5 years after the initiation of the treatment) (Chase, 1998; Obeso et al., 2000) . Such shortcomings of L-DOPA and other dopaminergic drugs have prompted a search for alternative treatment strategies that provide symptomatic benefits while avoiding the delayed motor complications associated with the long-term use of antiparkinsonian drugs. Several neurotransmitters have been implicated in the motor complications elicited by repeated dopamine receptor stimulation, including glutamate (Marin et al., 1996; Tzschentke and Schmidt, 1998; Calabresi et al., 2000) , cannabinoids (Souilhac et al., 1995; Zeng et al., 1999) , opioids (Henry and Brotchie, 1996) , and adenosine (Richardson et al., 1997; Kanda et al., 2000; Jenner, 2000) . Recently, the A 2A adenosine receptor has emerged as an attractive target for PD treatment by virtue of its concentrated expression in striatopallidal neurons and its modulation of dopamine receptor-mediated functions (Schiffmann et al., 1991; Fink et al., 1992; Ferré et al., 1997; Svenningsson et al., 1999) . In addition to the documented motor-activating feature of A 2A receptor antagonists (Richardson et al., 1997; Impagnatiello et al., 2000) , their minimal propensity for eliciting dyskinesia in L-DOPA-primed nonhuman primates (Kanda et al., 1998; Grondin et al., 1999) has further enhanced their therapeutic potential in PD.
To critically evaluate the involvement of A 2A receptors in L-DOPA-induced dyskinesia, we have adopted a rodent "priming" model in which behavioral sensitization is elicited by repeated treatment with a low dose of L-DOPA in unilateral 6-hydroxydopamine (6-OHDA)-lesioned mice (Carey, 1991; Henry et al., 1998) . The delayed induction of markedly increased contralateral rotation as well as several characteristic neurochemical adaptations in this rodent model closely resemble several behavioral and neurochemical features of L-DOPA-induced dyskinesia in parkinsonian nonhuman primates and in PD patients (Brotchie, 1998; Henry et al., 1998) . Thus, this behavioral sensitization model may provide useful information on the maladaptive neuronal plasticity that underlies L-DOPA-induced dyskinesia in PD. We examined the effect of genetic inactivation of A 2A receptors on chronic L-DOPA-induced behavioral sensitization using this rodent model of dyskinesia. Our genetic (knock-out) approach to A 2A receptor inactivation offers several advantages that complement standard pharmacological approaches, which are hindered by intrinsic limitations of partial specificity and efficacy. The results suggest that the A 2A receptor is required for the development and persistence of L-DOPA-induced behavioral sensitization in mice.
MATERIALS AND METHODS

Breeding of A 2A adenosine receptor knock-out mice
The A 2A adenosine receptor knock-out (A 2A KO) mouse line was generated in a pure 129-Steel genetic background as previously described (Chen et al., 1999a) and was maintained for Ͼ3 years through breeding by heterozygote intercrosses. For each of the present experiments, wildtype (WT) and A 2A KO littermates (both male and female) of the F4 generation were matched for gender, age (4 -5 months), and body weight (22-27 gm).
6-Hydroxydopamine lesions
All experiments were performed in accordance with Massachusetts General Hospital and National Institutes of Health Guidelines on the ethical use of animals. They were maintained in "home" cages with a 24 hr 1:1 light /dark cycle. To produce unilateral striatal dopamine depletion, the mice were pretreated with desipramine hydrochloride (25 mg / kg), to minimize damage to noradrenergic neurons. Under Avertin (2% 2,2,2-tribromoethanol and 1% amyl alcohol) anesthesia (20 ml / kg, i.p.), mice were inf used with 10 g of 6-OH DA (2.5 g/l in normal saline containing 0.05% of ascorbic acid) delivered by a microinf usion pump (1 l /min) into the left dorsal striatum at the following coordinates (from bregma: 1.1 mm anterior, 1.5 mm lateral, 2.0 mm ventral) (Franklin and Paxinos, 1997) .
Behavioral analysis
Behavioral analysis was performed by an observer, who was blinded to the genotype of the animals. Seven days after 6-OH DA lesioning, the W T and A 2A KO mice (n ϭ 9 -12) were randomly assigned to daily treatment with either low doses of L-DOPA (1.0, 1.8, and 2.5 mg / kg) or water for 3 weeks. All animals were pretreated with benserazide, a peripheral decarboxylase inhibitor (2.0 mg / kg, i.p., 20 min before L-DOPA or water injection). Contralateral rotation and grooming behaviors were evaluated in a test cage every other day from day 1 to day 14, and every 2 d from day 15 to day 20. The intensity and kinetic profile of L-DOPA-induced contralateral behavior was monitored, and recordings were established by monitoring the number of complete (360°) rotations ipsilateral and contralateral to the lesion in a 60 min testing period immediately after the injection of L-DOPA or water. Stereotyped grooming behavior was scored (in a 60 min test period immediately after the injection) by the observer using the following scale: 0 ϭ inactive (mostly motionless without stereotypies), 1 ϭ active without grooming (coordinated movements/exploration without stereotypies), 2 ϭ mild grooming (sporadic face washing and head stretching), 3 ϭ moderate grooming (frequent but discontinuous face washing, rearing and standing with hind limbs), 4 ϭ vigorous grooming (repetitive face and body washing in a sequential chain of grooming activity), and 5 ϭ intensive grooming (grooming of any kind with forepaws interspersed with vigorous grooming of the hindflank or anogenital region).
Biochemical assessments
Striatal content of DA and DOPAC. In a separate experiment, 7 d after 6-OH DA injection, mice were killed by rapid cervical dislocation, and their striata were dissected and assayed for catecholamines by standard reverse-phase HPLC with electrochemical detection, as described previously .
Dopamine transporter binding autoradiography. Dopamine transporter (DAT) binding was assessed using the radioligand [ 3 H]-mazindol (specific activity ϭ 24 C i /mmol; DuPont N EN, Boston, M A) in mice killed 1 week after 6-OH DA injection (and before any L-DOPA treatment) or 4 weeks after the 6-OH DA injection (i.e., 3 weeks after the first daily L-DOPA treatment and 24 hr after the last L-DOPA treatment). T wenty micrometer coronal sections at the levels of anterior, middle, and posterior striatum were processed for [ 3 H]-mazindol binding as previously described ). Specific striatal [
3 H]-mazindol binding (femtomoles per milligram of tissue) was calculated by subtracting nonspecific binding (in the presence of 100 M unlabeled nomifensine) from total binding.
In situ hybridization histochemistr y. In situ hybridization histochemistry with cRNA probes was performed according to protocols described in previous studies (Moratalla et al., 1996a,b) . Mouse brain sections were post-fixed in buffered 4% paraformaldehyde, acetylated in acetic anhydride, and dehydrated in graded ethanol. Sections were hybridized with a 35 S-labeled RNA probe (150,000 cpm /l buffer) specific for the rat prodynorphin cDNA (provided by J. Douglass) (C ivelli et al., 1985) in a hybridization buffer described previously (Moratalla et al., 1996a,b) . After hybridization, sections were washed and then treated with RNase A (100 g /ml), and washed again to final strength in 0.1ϫ SSC at 70°C for 30 min. The slides were rinsed, dried, and exposed to BioMax MR films (Amersham Biosciences, Arlington Heights, IL) for 15-20 d.
Image anal ysis. Optical densities on the film were determined using a computing densitometer equipped with an image analysis program (model 300A; Molecular Dynamics, Sunny vale, CA). Approximately three or four sections through the striatum, at rostral and middle levels, were analyzed for each mouse. For each section, dynorphin mRNA levels were determined by optical densities that were in the 6-OH DA lesioned side (left) and the contralateral side (right). Dynorphin mRNA levels from 6-OH DA lesioned side were expressed as a percentage of the contralateral (unlesioned) side because previous experiments have demonstrated that a unilateral 6-OH DA lesion did not alter dynorphin mRNA expression in the contralateral striatum (C enci et al., 1993) .
Statistical analysis
All data are expressed as group mean Ϯ SEM and analyzed using "SAS" or "SPSS" statistical programs. The significance of differences between two genotypes across multiple treatment groups was evaluated by splitplot ANOVA for repeated measures followed by Fisher's least significant difference (L SD) comparison test. The significance of differences between responses on treatment day 1 and subsequent treatment days was evaluated by one-way ANOVA for repeated measures, followed by Dunnett's test. Selective comparison of specific treatment day versus day 1 was evaluated by the randomization test for matched pairs (Siegel and C astellan, 2000) . Grooming behavioral data were analyzed by the nonparametric Kruskal -Wallis test followed by the Mann -Whitney U test. The differences in dynorphin mRNA levels between W T and KO groups were analyzed by Student's t test.
RESULTS
Intrastriatal 6-OHDA injection produced indistinguishable dopaminergic neurotoxicity in WT and A 2A KO mice
Previous studies in our laboratory and others showed that inactivation of A 2A receptors by either genetic ablation or pharmacological blockade protects against brain injuries induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , kainic acid (Jones et al., 1998a,b) , or middle cerebral artery occlusion (Monopoli et al., 1998; Chen et al., 1999a) . Accordingly, we first determined whether the dopaminergic lesion induced by 6-OHDA differs between A 2A KO and WT mice. The administration of 6-OHDA into the left striatum of mice significantly reduced striatal levels of dopamine as well as its main metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) ipsilateral to the lesion (Table 1) . These reductions were indistinguishable between WT and A 2A KO mice.
The extent of the lesion was also assessed by determining the DAT binding density in striatum before and after chronic L-DOPA treatment. Seven days after the unilateral 6-OHDA injection, striatal DAT binding density decreased significantly in the ipsilateral striatum of L-DOPA-naive mice (Table 1) . Consistent with the dopamine content data, the reduction of DAT binding on the ipsilateral side was virtually identical between WT and A 2A KO groups (Table 1) . Similarly, in the mice treated with L-DOPA daily for 3 weeks, no difference in the reduction of ipsilateral DAT density was found between the two genotypes. There was also no difference between KO and WT mice with respect to the slight rise in contralateral DAT binding density observed after the repeated L-DOPA treatments. [The basis for this rise is unclear, although a similar elevation in DAT binding density in unlesioned striatum after repeated L-DOPA treatment has been reported by others (Ikawa et al., 1993) .] Thus, these results confirm that the intrastriatal injection of 6-OHDA produced similar dopaminergic neurotoxicity, setting the stage for a meaningful comparison of behavioral sensitization in hemiparkinsonian WT and A 2A KO mice. These data also indicate that the neuroprotective effect of A 2A receptor inactivation against MPTP toxicity does not necessarily apply to all models of PD.
Lack of persistent rotational sensitization to chronic L-DOPA treatment in hemiparkinsonian A 2A KO mice
To evaluate A 2A receptor involvement in L-DOPA-induced behavioral sensitization, we treated WT and A 2A KO mice with 20 daily doses of L-DOPA beginning 1 week after unilateral intrastriatal injection of 6-OHDA. L-DOPA at the very low dose of 1.0 mg/kg, intraperitoneally, did not result in any significant contralateral or ipsilateral turning behavior in either WT and A 2A KO mice (Fig. 1 A) as compared with the vehicle-treated group in which only a weak net ipsilateral response (8 Ϯ 1 and 5 Ϯ 5 net ipsilateral turns/hr on day 1 in WT and A 2A KO mice, respectively) could be seen consistently throughout the test period (data not shown). However, the administration of L-DOPA at higher but still modest doses 1.8 and 2.5 mg/kg produced a marked behavioral sensitization in WT mice ( Fig. 1 B,C, respectively) . Specifically, after a lag time of 3 d, mice treated daily with 1.8 mg/kg L-DOPA began to develop an increased contralateral rotational response that reached a maximum by day 9 (Fig. 1 B) . In WT mice the sensitized response persisted unabated for the duration of the 20 d treatment period. However, the behavioral pattern induced by repeated L-DOPA treatment in A 2A KO mice markedly differed from that in WT mice (Fig. 1 B) (F (8,160) ϭ 2.92; p Ͻ 0.01; split-plot ANOVA). Although A 2A KO mice displayed a trend of gradual enhancement of contralateral rotations reaching an apparent maximum between days 5 and 9 of daily 1.8 mg/kg L-DOPA treatment, they failed to develop statistically significant behavioral sensitization at this dosage (one-way ANOVA for repeated measurements; n ϭ 12; F (8,99) ϭ 1.677; p ϭ 0.118). Most strikingly, any enhancement of rotational response to L-DOPA in A 2A KO mice was not maintained after day 9. Instead, by day 14 the response to L-DOPA had returned to baseline (i.e., that on day 1) where it remained for the rest of the experiment. As previously noted and discussed, acute dopaminergic stimulation of motor activity (as on day 1) is not enhanced in A 2A KO mice, in contrast to the demonstrated potentiating effect of A 2A antagonists on motor activity (Chen et al., 2000) .
Because A 2A KO mice primarily failed to develop significantly sensitized rotational behavior, the possibility arose that using this low dose of L-DOPA (1.8 mg/kg) a "threshold" response needed to elicit sustained behavioral sensitization was reached in WT but not KO mice. Indeed, the acute motor response to dopaminergic stimulation (e.g., on day 1) (Fig. 1 B) may have been slightly lower in A 2A KO than in WT mice (as we and others have previously observed; Ledent et al., 1997; Chen et al., 2000) . To address this possibility we attempted to overcome such a threshold effect by examining the influence of A 2A receptor inactivation on the duration of sensitization induced by a higher dose of L-DOPA. As shown in the Figure 1C , 2.5 mg/kg L-DOPA produced substantially greater contralateral turning (compared with 1.8 mg/kg daily) for both the initial and maximal response, with the latter occurring earlier (by day 7) using the higher dose, in both WT and A 2A KO mice. Nevertheless, the rotational sensitization was again maintained for the duration of daily L-DOPA treatment only in WT mice. By contrast, the response to this higher dose of L-DOPA in A 2A KO mice, after apparently sensitizing with a peak on day 5 ( p Ͻ 0.05 only for day 5 compared with day 1 by the randomization test for matched pairs, and p Ͼ 0.05 by one-way ANOVA for repeated measurements), reverted by day 17 to that observed on day 1. Note that the absence of persistent sensitization in KO mice was as prominent at 2.5 mg/kg as it was at 1.8 mg/kg L-DOPA, although their peak rotational responses at the higher dose exceeded the peak responses observed in WT mice at the lower dose. Thus, these data confirm the effect of A 2A receptor inactivation on the development and particularly the maintenance of L-DOPA-induced rotational sensitization and rule out the possibility that it can be explained by nonspecific subthreshold responses to L-DOPA in A 2A KO mice.
Because development of L-DOPA-induced behavioral sensitization is associated with a progressively shortened onset and duration of action, we also compared how the kinetics of L-DOPA-induced responses changed over the 3 week course of daily treatments in WT and A 2A KO mice. As shown in Figure  2 A, the time to reach the peak contralateral turning response to a single dose of L-DOPA (1.8 mg/kg) was progressively shortened in WT mice (from 20 -30 min on day 1, to 20 min on day 11, to 10 min on day 20). In contrast, the time to reach the peak response in A 2A KO animals remained virtually unchanged throughout the treatment (ϳ20 min for days 1, 11 and 20). Moreover, the number of contralateral rotations occurring over the initial 10 min after L-DOPA administration increased steadily and significantly in WT but not A 2A KO mice from day 1 to day 20 (Fig. 2 B) . These results further support an important role for the A 2A receptor in the adaptive behavioral responses to chronic L-DOPA treatment.
Lack of sensitized grooming responses to chronic L-DOPA in hemiparkinsonian A 2A KO mice
We also examined the effect of A 2A receptor inactivation on chronic L-DOPA-induced grooming behaviors. Grooming is by its nature a stereotyped behavior, and it has been proposed to share common neurochemical features with L-DOPA-induced dyskinesia in primates (Graybiel et al., 2000) . Daily treatment with vehicle did not induce any significant grooming behavior in WT and KO mice of 129-Steel genetic background (most average scores were Ͻ1, n ϭ 2 for WT and n ϭ 3 for KO mice, respectively; data not shown). However, daily L-DOPA administration to WT mice (Fig. 3) increased the frequency and intensity of grooming after repeated challenges, reaching its maximum after 11 d at the lowest dose tested (1.0 mg/kg) (Fig. 3A) or 9 d using the intermediate dose (1.8 mg/kg) ( Fig. 3B ) (n ϭ 10 -12; p Ͻ 0.05; Kruskal-Wallis test followed by Mann-Whitney U test). Grooming responses then remained enhanced throughout the duration of treatment (Fig. 3) . In A 2A KO mice, by contrast, the grooming responses to either of these daily doses of L-DOPA showed no significant sensitization over the entire 3 week period ( Finally, we also examined the effect of A 2A receptor inactivation on chronic L-DOPA-induced striatal neuronal activity using dynorphin mRNA as a cellular readout. Dynorphin mRNA is predominantly coexpressed with D 1 dopamine receptor mRNA in striatonigral neurons (the "direct" pathway) (Gerfen et al., 1990; Le Moine et al., 1990) . The L-DOPA-induced reversal of the 6-OHDA-induced reduction in dynorphin mRNA has been associated with the development of L-DOPA-induced dyskinesia in parkinsonian animals (Andersson et al., 1999; Jenner, 2000) . In situ hybridization analysis shows that 6-OHDA lesioning reduced dynorphin mRNA levels in the ipsilateral striatum of both WT and KO mice. Consistent with previous reports (Andersson et al., 1999; Henry et al., 1999; Pirker et al., 2001) , chronic treatment with L-DOPA dose-dependently reverses the 6-OHDA-induced reduction in dynorphin mRNA to normal levels in WT mice (Fig.  4) (n ϭ 8 -9; p Ͼ 0.05; compared with contralateral striatum, paired Student's t test). L-DOPA did not, however, increase dynorphin mRNA above normal levels in WT mice (as others have observed; Andersson et al., 1999; Henry et al., 1999) , probably because of the particularly low doses of L-DOPA tested here (1.0 -2.5 mg/kg, threefold less than in the otherwise similar studies). In contrast, chronic L-DOPA treatment failed to reverse the reduction in dynorphin mRNA to normal levels in A 2A KO mice (Fig. 4) . Thus, the A 2A receptor may contribute to the altered neuronal activity of the "direct" striatonigral pathway that is associated chronic L-DOPA-induced behavioral changes. 
DISCUSSION The A 2A adenosine receptor is required for L-DOPA-induced behavioral sensitization
The main finding of our study is that genetic inactivation of A 2A receptors abolished sustained behavioral sensitization in response to repeated L-DOPA treatment in mice. Our results clearly show that WT mice developed progressively enhanced contralateral rotational, whereas A 2A KO mice developed only a trend toward L-DOPA-induced sensitization of rotational responses that appeared milder than in WT mice and primarily failed to reach statistical significance. The time to reach peak rotation progressively shortened in WT but not A 2A KO mice. In keeping with the lack of sustained rotational behavioral sensitization, A 2A receptor inactivation also prevented or markedly reduced the induction of grooming responses. These altered behavioral responses were further substantiated by the neurochemical finding that repeated L-DOPA treatment reversed the 6-OHDA-induced reduction of striatal dynorphin mRNA levels in WT but not A 2A KO mice. Thus, the absence of chronic L-DOPA-induced sensitization at the behavioral (contralateral rotation and grooming) and cellular (dynorphin mRNA) levels in hemiparkinsonian mice lacking A 2A receptors strongly suggests that A 2A receptors are required for L-DOPA-induced behavioral sensitization.
The most striking finding of the present study is that 6-OHDAlesioned mice lacking the A 2A receptors do not maintain sensitized rotational motor responses to repeated L-DOPA administration. Although the maintenance of behavioral sensitization, like its induction and expression, is recognized as a mechanistically discrete phase (Wolf, 1998; Chase and Oh, 2000; Li et al., 2000; Vanderschuren and Kalivas, 2000) , relatively little is known about the unique molecular pathways leading to the persistence of this phenomenon, which can last for months or years under some circumstances (Robinson and Becker, 1986 ). The present data indicate that A 2A receptors may play a critical role in the maintenance of L-DOPA-induced motor sensitization. Thus, they suggest that endogenous adenosine acting on (presumably striatal) A 2A receptors may facilitate the long-term adaptive changes induced by chronic L-DOPA exposure.
The reversal of an apparent sensitization to L-DOPA ( Fig.  1 B,C) in the absence of functional A 2A receptors could be explained by the rapid development of tolerance. This consideration is prompted by the well documented phenomenon of tolerance to the motor effects of the nonspecific adenosine receptor antagonist caffeine (for review, see Fredholm et al., 1999) . However, several studies have now shown that the motor activation induced by a specific A 2A receptor antagonist shows no tolerance after chronic intermittent administration (Halldner et al., 2000; Pinna et al., 2001) . Moreover, in a preliminary study the locomotor response to self-administered intravenous cocaine showed no tolerance in A 2A KO mice, in contrast to the marked tolerance that develops in their WT littermates (Rocha et al., 2001) . Therefore, tolerance is unlikely to account for a reversal of newly developed sensitization in A 2A KO mice. The absence of active A 2A receptormediated maintenance of the adaptive changes underlying sensitization may offer a better explanation.
The absence of sustained sensitization to repeated L-DOPA treatment in mice lacking the A 2A receptor likely reflects a broader phenotype of attenuated adaptive motor responses to intermittent dopaminergic stimulation. Indeed, we have found that the robust locomotor sensitization to the indirect dopamine agonist amphetamine in WT mice is completely absent in their A 2A KO littermates (Chen et al., 1999b) . In line with these findings, a withdrawal syndrome that develops after chronic repeated alcohol administration was attenuated in mice lacking the A 2A receptor and in mice treated with the specific A 2A antagonist ZM 241385 (El Yacoubi et al., 2001) . However, the extent to which acute pharmacological blockade of the A 2A receptor parallels the A 2A KO phenotype in preventing sensitized responses to chronic dopaminergic stimulation remains to be clarified. For example, although one study has raised the possibility that L-DOPA-induced motor sensitization may be prevented by paired exposure to a specific A 2A antagonist (Pinna et al., 2001) , another has suggested that a specific A 2A agonist can have the same effect on methamphetamine-induced motor sensitization (Shimazoe et al., 2000) . Nevertheless when taken together, A 2A receptor studies based on either pharmacological or genetic approaches have consistently pointed to an important role for this receptor in adaptive motor behaviors.
Potential mechanisms by which the A 2A receptor facilitates L-DOPA-induced behavioral sensitization
Considerable research effort has been devoted to clarifying the anatomical and neurochemical basis of sensitized behavioral responses to dopaminergic stimuli. Although this phenomenon has been well localized to the mesolimbic and nigrostriatal dopaminergic systems of the basal ganglia, less is clear about the specific dopaminergic receptor subtypes, as well as the other neurotransmitters and the intracellular signaling cascades mediating these adaptive changes (Pierce and Kalivas, 1997) . Both D 1 -and D 2 -like receptors have been implicated in L-DOPA-induced sensitization (Morelli and Di Chiara, 1987; Blanchet et al., 1995 , Bordet et al., 2000 . Activation of A 2A receptors has been shown to antagonize D 2 receptor-mediated neurotransmitter release, immediate-early gene expression, and psychomotor stimulation (Ferré et al., 1997; Svenningsson et al., 1999) . Thus, the A 2A receptor may modulate L-DOPA-induced behavioral sensitization through its cellular-level interaction with the D 2 receptor in striatopallidal neurons (of the "indirect" pathway), which express both A 2A and D 2 receptors. Within striatal neurons multiple intracellular signaling cascades, the cAMP pathway in particular, have also been implicated in the basal ganglia plasticity that underlies sensitization to dopaminergic stimulation (Chase and Oh, 2000; Jenner, 2000) . For example, repeated treatment with L-DOPA or other dopaminergic stimuli has been shown to enhance phosphorylation and activation of cAMP pathway targets, including dopamine-and cAMP-dependent phosphoprotein (DARPP-32) and cAMP-response element binding protein and expression of the long half-life transcription factor FosB (Barone et al., 1994; Moratalla et al., 1996a; Pierce and Kalivas, 1997; Chase and Oh, 2000; Dunah et al., 2000) . The A 2A receptor, which is positively coupled to adenylate cyclase and cAMP production through G s , may affect L-DOPA-induced neurochemical and behavioral changes by influencing this pathway. In this regard, a recent study shows that D 2 receptor blockade induces phosphorylation of DARPP-32 protein in WT but not A 2A KO mice, indicating a critical role for A 2A receptors in striatal cellular signaling involving the cAMP pathway (Svenningsson et al., 2000) . Further studies are needed to clarify the exact role of cAMP signaling in the A 2A receptormediated modulation of behavioral sensitization.
The A 2A receptor may also exert its effect on behavioral sensitization through a network-level interaction with D 1 receptors, which are primarily expressed on non-A 2A receptor-expressing striatonigral neurons (of the "direct" pathway). Interestingly, Pollack et al. (1997) showed that "priming" by the dopamine agonist apomorphine leads to the recruitment of D 2 receptorexpressing in concert with D 1 receptor-expressing striatal neurons to produce enhanced behavioral and cellular responses. Similarly, in striatal slices, activation of the D 2 or A 2A receptors transynaptically interacts with D 1 receptors to modulate phosphorylation of DARPP-32, an effect that was blocked by tetrodotoxin (Lindskog et al., 1999) . These studies illustrate clearly a functional cross-talk between the indirect pathway (coexpressing A 2A and D 2 receptors) and the direct pathway (expressing D 1 receptors) at the network level. Furthermore, in striatonigral neurons of the "direct" pathway, the increased expression of mRNAs encoding neuropeptides substance P and dynorphin has been associated with the development of behavioral sensitization in response to repeated L-DOPA (Engber et al., 1991; Herrero et al., 1995; Cenci et al., 1998; Andersson et al., 1999; Pirker et al., 2001) , indicating overactivity of the (D 1 -expressing) "direct" pathway in L-DOPA-sensitized animals. Our finding that chronic L-DOPA treatment reverses the 6-OHDA-induced reduction in striatal dynorphin mRNA in WT but A 2A KO mice supports this notion. It is also consistent with our preliminary finding that D 1 agonist challenge after the chronic L-DOPA treatment schedule used in this study resulted in enhanced contralateral turning (compared with baseline rotational response to D 1 stimulation before L-DOPA treatments) in WT but not A 2A KO mice (S. Fredduzzi, M. A. Schwarzschild, and J.-F. Chen, unpublished observations). Thus, A 2A receptor modulation of dopaminergic sensitization may involve both D 1 and D 2 dopamine receptors in the "direct" striatonigral and "indirect" striatopallidal pathways, respectively.
Finally, A 2A receptors may modulate L-DOPA-induced behavioral sensitization by modulating presynaptic release of several neurotransmitters such as dopamine, glutamate, and GABA, all critically involved in the development of dopamine-associated behavioral sensitization (Pierce and Kalivas, 1997) . Although activation of A 1 receptors at presynaptic terminals markedly inhibits the release of a wide-range of neurotransmitters, activation of A 2A receptors has been shown to enhance dopamine release in striatum and nucleus accumbens (Okada et al., 1996; Sebastiao and Ribeiro, 1996) . This is further supported by the recent demonstration that basal dopamine levels in striatum, measured by microdialysis, were significantly lower in A 2A KO mice than that of WT littermates (Dassesse et al., 2001) , and is consistent with our findings that depolarization-elicited dopamine release was significantly attenuated in striatal synaptosomes from A 2A KO mice (T. Turner, J.-F. Chen, and M. A. Schwarzschild, unpublished observations). Thus, inactivation of A 2A receptors may reduce dopamine release resulting in hypo-dopaminergic activity, and in turn, attenuated L-DOPA sensitization.
In addition to dopamine, glutamate and its release from nerve terminals in the striatum, nucleus accumbens, and ventral mesencephalon have been strongly implicated in the different phases of sensitization (for review, see Wolf, 1998) . A 2A receptors serve a well established excitatory CNS role (Sebastiao and Ribeiro, 1996) attributed to their facilitative effects on glutamate release, which have been demonstrated in striatum (Popoli et al., 1995) as well as cortex (O'Regan et al., 1992) Thus, an attenuation of glutamate release in A 2A KO mice may contribute to their phenotype of attenuated L-DOPA-induced sensitization. Alternatively, A 2A receptor-enhancement of GABA release particularly from A 2A receptor-expressing striatopallidal neurons (Kurokawa et al., 1994; Mayfield et al., 1996) also offers a plausible basis for the reduced L-DOPA sensitization in KO mice. Modulation of striatal acetylcholine (as well as dopamine) release by A 2A receptors (Zetterstrom and Fillenz, 1990; Kurokawa et al., 1994 Kurokawa et al., , 1996 are also potential targets of A 2A receptors involvement.
Therapeutic implications for PD
The lack of persistent L-DOPA-induced behavioral sensitization in A 2A KO mice has implications for the development of A 2A antagonists as a potential therapeutic intervention for PD and psychiatric disorders associated with dopaminergic system dysfunction. A 2A antagonists are being developed as novel therapeutic agents for PD treatment based primarily on their well documented capacity to enhance motor function. In animal models of PD, A 2A antagonists alone or in combination with L-DOPA reverse parkinsonian motor deficits in rodents and nonhuman primates (Richardson et al., 1997; Kanda et al., 1998; Grondin et al., 1999) . In addition, we have recently demonstrated that A 2A antagonists attenuate dopaminergic neurotoxicity in the MPTP model of PD in mice, raising the possibility that A 2A antagonists may offer neuroprotective as well as symptomatic benefits in PD treatment ). The present findings suggest an additional potential benefit of A 2A receptor inactivation as adjunctive therapy with L-DOPA in PD. Persistent rotational sensitization and grooming sensitization induced by repeated L-DOPA administration was dependent after the presence of the A 2A receptor, and thus A 2A antagonists may attenuate the maladaptive dyskinetic responses to chronic L-DOPA treatment in PD.
Together, these multiple potential therapeutic benefits of A 2A antagonists (motor enhancement, neuroprotection against dopaminergic toxicity, and the prevention of dyskinesia), coupled with their low risk of CNS side effects (given the relatively discrete striatal expression of the A 2A receptor) should greatly encourage their development as a promising treatment for PD. The first clinical trials to evaluate a specific A 2A antagonist are now targeting advanced PD patients suffering from dyskinesias and related motor fluctuations. This strategy is supported the preclinical evidence that A 2A receptor blockade may enhance motor function without inducing or exacerbating dyskinesias (Kanda et al., 1998; Grondin et al., 1999) . However, the new findings suggesting additional benefits of attenuated dyskinesia development and disease progression in PD provide a strong rationale for considering the use of A 2A antagonists early in the course of the disease.
